Hisashi Harada

12PUBLICATIONS
28CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 11, 2026
Proteasome inhibition enhances lysosome-mediated targeted protein degradation.

|Apr 27, 2026
Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention.

|Jan 10, 2026
A Computational Approach for the Prediction of p53 and BCL-2 Protein-Protein Interactions.

Colette Creamer, Victoria Neely, Hisashi Harada

|Jul 12, 2025
Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells.

Natalie Luffman, Fereshteh Ahmadinejad, Ryan M Finnegan

|Mar 04, 2025
A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment.

Tareq Saleh, Edward F Greenberg, Anthony C Faber

|Sep 20, 2024
Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis.

Kranthi Kumar Chougoni, Victoria Neely, Boxiao Ding

Pageof 2

Frequent Collaborators

6 joint publications

David A Gewirtz

3 joint publications

Tareq Saleh

2 joint publications

Ahmed M Elshazly

2 joint publications

Senthil K Radhakrishnan